Tepezza, a drug approved in 2020 for the treatment of thyroid eye disease, appears to affect the hearing of up to 65% of the patients who take it, according to a study presented at the Endocrine Society’s annual meeting
Hearing-related symptoms were reported in 10% of patients in clinical trials, but the findings of this later study show even worse outcomes.
Tepezza, the brand name for teprotumumab, is the only drug approved by the FDA for thyroid eye disease, which is an autoimmune disease that can cause the eyes to become inflamed. Mostly associated with Grave’s disease, thyroid eye disease can include symptoms such as double vision, dry, red, watery, or bulging eyes, “a stare,” and other vision problems.
If you or someone you know has taken Tepezza and suffered hearing problems or loss, please reach out to Skinner Accident & Injury Lawyers. We might be able to help.